Do analysts prefer CNTN or FWDI?

Forward Industries has a consensus price target of $12.50, suggesting a potential upside of 62.34%. Given Forward Industries' stronger consensus rating and higher possible upside, analysts plainly believe Forward Industries is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Forward Industries 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Does the media prefer CNTN or FWDI?

In the previous week, Forward Industries had 5 more articles in the media than Hillstream Biopharma. MarketBeat recorded 6 mentions for Forward Industries and 1 mentions for Hillstream Biopharma. Forward Industries' average media sentiment score of 0.16 beat Hillstream Biopharma's score of 0.00 indicating that Forward Industries is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hillstream Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Forward Industries 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CNTN or ACTG?

Acacia Research has a consensus price target of $6.00, indicating a potential upside of 33.04%. Given Acacia Research's stronger consensus rating and higher possible upside, analysts clearly believe Acacia Research is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Acacia Research 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to CNTN or ACTG?

In the previous week, Acacia Research had 1 more articles in the media than Hillstream Biopharma. MarketBeat recorded 2 mentions for Acacia Research and 1 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 0.00 beat Acacia Research's score of -0.06 indicating that Hillstream Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hillstream Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Acacia Research 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer TROO or CNTN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TROOPS 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, TROO or CNTN?

TROOPS has higher revenue and earnings than Hillstream Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TROOPS $17.10M 14.43 -$27.91M N/A N/A Hillstream Biopharma N/A N/A -$35.92M -$0.50 N/A

Is TROO or CNTN more profitable?

TROOPS's return on equity of 0.00% beat Hillstream Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets TROOPS N/A N/A N/A Hillstream Biopharma N/A -20.06% -15.90%

Does the media favor TROO or CNTN?

In the previous week, TROOPS had 20 more articles in the media than Hillstream Biopharma. MarketBeat recorded 21 mentions for TROOPS and 1 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 0.00 beat TROOPS's score of -0.37 indicating that Hillstream Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TROOPS 1 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 5 Negative mention(s) 3 Very Negative mention(s) Neutral Hillstream Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CEPO or CNTN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cantor Equity Partners 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, CEPO or CNTN?

Cantor Equity Partners is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cantor Equity Partners N/A N/A -$6.66M -$0.29 N/A Hillstream Biopharma N/A N/A -$35.92M -$0.50 N/A

Is CEPO or CNTN more profitable?

Cantor Equity Partners' return on equity of 0.00% beat Hillstream Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Cantor Equity Partners N/A N/A -0.74% Hillstream Biopharma N/A -20.06% -15.90%

Does the media favor CEPO or CNTN?

In the previous week, Cantor Equity Partners had 1 more articles in the media than Hillstream Biopharma. MarketBeat recorded 2 mentions for Cantor Equity Partners and 1 mentions for Hillstream Biopharma. Cantor Equity Partners' average media sentiment score of 1.85 beat Hillstream Biopharma's score of 0.00 indicating that Cantor Equity Partners is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cantor Equity Partners 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Hillstream Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend CNTN or MAAS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Maase 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, CNTN or MAAS?

Maase has higher revenue and earnings than Hillstream Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hillstream Biopharma N/A N/A -$35.92M -$0.50 N/A Maase $109.05M 2.46 -$27.36M N/A N/A

Is CNTN or MAAS more profitable?

Maase's return on equity of 0.00% beat Hillstream Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Hillstream Biopharma N/A -20.06% -15.90% Maase N/A N/A N/A

Does the media refer more to CNTN or MAAS?

In the previous week, Maase had 2 more articles in the media than Hillstream Biopharma. MarketBeat recorded 3 mentions for Maase and 1 mentions for Hillstream Biopharma. Maase's average media sentiment score of 0.33 beat Hillstream Biopharma's score of 0.00 indicating that Maase is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hillstream Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Maase 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Hillstream Biopharma (CNTN) Competitors

$2.30 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$2.38 +0.08 (+3.26%)

As of 05:44 AM Eastern

Compare

CNTN vs. FWDI, ACTG, TROO, CEPO, and MAAS

Should you buy Hillstream Biopharma stock or one of its competitors? Hillstream Biopharma's main competitors and comparable companies include Forward Industries (FWDI), Acacia Research (ACTG), TROOPS (TROO), Cantor Equity Partners (CEPO), and Maase (MAAS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "multi-sector holdings" industry.

How does Hillstream Biopharma compare to Forward Industries?

Hillstream Biopharma (NASDAQ:CNTN) and Forward Industries (NASDAQ:FWDI) are both small-cap finance companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

In the previous week, Forward Industries had 5 more articles in the media than Hillstream Biopharma. MarketBeat recorded 6 mentions for Forward Industries and 1 mentions for Hillstream Biopharma. Forward Industries' average media sentiment score of 0.16 beat Hillstream Biopharma's score of 0.00 indicating that Forward Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hillstream Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Forward Industries	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Hillstream Biopharma has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market. Comparatively, Forward Industries has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

Hillstream Biopharma has higher earnings, but lower revenue than Forward Industries. Hillstream Biopharma is trading at a lower price-to-earnings ratio than Forward Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hillstream Biopharma	N/A	N/A	-$35.92M	-$0.50	N/A
Forward Industries	$53.12M	10.70	-$166.97M	$0.12	64.17

Forward Industries has a consensus price target of $12.50, suggesting a potential upside of 62.34%. Given Forward Industries' stronger consensus rating and higher possible upside, analysts plainly believe Forward Industries is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Forward Industries	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Hillstream Biopharma has a net margin of 0.00% compared to Forward Industries' net margin of -2,073.82%. Forward Industries' return on equity of -18.05% beat Hillstream Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-20.06%	-15.90%
Forward Industries	-2,073.82%	-18.05%	-17.03%

1.2% of Hillstream Biopharma shares are owned by institutional investors. 3.3% of Hillstream Biopharma shares are owned by insiders. Comparatively, 15.9% of Forward Industries shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Forward Industries beats Hillstream Biopharma on 10 of the 15 factors compared between the two stocks.

How does Hillstream Biopharma compare to Acacia Research?

Hillstream Biopharma (NASDAQ:CNTN) and Acacia Research (NASDAQ:ACTG) are both small-cap finance companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations.

Hillstream Biopharma has a net margin of 0.00% compared to Acacia Research's net margin of -5.39%. Acacia Research's return on equity of 0.44% beat Hillstream Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-20.06%	-15.90%
Acacia Research	-5.39%	0.44%	0.33%

In the previous week, Acacia Research had 1 more articles in the media than Hillstream Biopharma. MarketBeat recorded 2 mentions for Acacia Research and 1 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 0.00 beat Acacia Research's score of -0.06 indicating that Hillstream Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hillstream Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Acacia Research	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Acacia Research has a consensus price target of $6.00, indicating a potential upside of 33.04%. Given Acacia Research's stronger consensus rating and higher possible upside, analysts clearly believe Acacia Research is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Acacia Research	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

1.2% of Hillstream Biopharma shares are owned by institutional investors. Comparatively, 86.7% of Acacia Research shares are owned by institutional investors. 3.3% of Hillstream Biopharma shares are owned by company insiders. Comparatively, 1.7% of Acacia Research shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Acacia Research has higher revenue and earnings than Hillstream Biopharma. Acacia Research is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hillstream Biopharma	N/A	N/A	-$35.92M	-$0.50	N/A
Acacia Research	$285.23M	1.54	$21.68M	-$0.15	N/A

Hillstream Biopharma has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market. Comparatively, Acacia Research has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market.

Summary

Acacia Research beats Hillstream Biopharma on 10 of the 15 factors compared between the two stocks.

How does Hillstream Biopharma compare to TROOPS?

TROOPS (NASDAQ:TROO) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap finance companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

In the previous week, TROOPS had 20 more articles in the media than Hillstream Biopharma. MarketBeat recorded 21 mentions for TROOPS and 1 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 0.00 beat TROOPS's score of -0.37 indicating that Hillstream Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TROOPS	1 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	5 Negative mention(s)	3 Very Negative mention(s)	Neutral
Hillstream Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

1.2% of Hillstream Biopharma shares are owned by institutional investors. 1.1% of TROOPS shares are owned by insiders. Comparatively, 3.3% of Hillstream Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

TROOPS has higher revenue and earnings than Hillstream Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TROOPS	$17.10M	14.43	-$27.91M	N/A	N/A
Hillstream Biopharma	N/A	N/A	-$35.92M	-$0.50	N/A

TROOPS has a beta of 3.55, meaning that its share price is 255% more volatile than the broader market. Comparatively, Hillstream Biopharma has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TROOPS	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

TROOPS's return on equity of 0.00% beat Hillstream Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TROOPS	N/A	N/A	N/A
Hillstream Biopharma	N/A	-20.06%	-15.90%

Summary

TROOPS beats Hillstream Biopharma on 6 of the 9 factors compared between the two stocks.

How does Hillstream Biopharma compare to Cantor Equity Partners?

Cantor Equity Partners (NASDAQ:CEPO) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap finance companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cantor Equity Partners	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

1.2% of Hillstream Biopharma shares are held by institutional investors. 3.3% of Hillstream Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cantor Equity Partners has a beta of -0.05, meaning that its share price is 105% less volatile than the broader market. Comparatively, Hillstream Biopharma has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market.

Cantor Equity Partners' return on equity of 0.00% beat Hillstream Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cantor Equity Partners	N/A	N/A	-0.74%
Hillstream Biopharma	N/A	-20.06%	-15.90%

In the previous week, Cantor Equity Partners had 1 more articles in the media than Hillstream Biopharma. MarketBeat recorded 2 mentions for Cantor Equity Partners and 1 mentions for Hillstream Biopharma. Cantor Equity Partners' average media sentiment score of 1.85 beat Hillstream Biopharma's score of 0.00 indicating that Cantor Equity Partners is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cantor Equity Partners	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Hillstream Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cantor Equity Partners is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cantor Equity Partners	N/A	N/A	-$6.66M	-$0.29	N/A
Hillstream Biopharma	N/A	N/A	-$35.92M	-$0.50	N/A

Summary

Cantor Equity Partners beats Hillstream Biopharma on 6 of the 10 factors compared between the two stocks.

How does Hillstream Biopharma compare to Maase?

Hillstream Biopharma (NASDAQ:CNTN) and Maase (NASDAQ:MAAS) are both small-cap finance companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Maase	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

1.2% of Hillstream Biopharma shares are held by institutional investors. 3.3% of Hillstream Biopharma shares are held by insiders. Comparatively, 87.6% of Maase shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Maase had 2 more articles in the media than Hillstream Biopharma. MarketBeat recorded 3 mentions for Maase and 1 mentions for Hillstream Biopharma. Maase's average media sentiment score of 0.33 beat Hillstream Biopharma's score of 0.00 indicating that Maase is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hillstream Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maase	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Maase's return on equity of 0.00% beat Hillstream Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-20.06%	-15.90%
Maase	N/A	N/A	N/A

Maase has higher revenue and earnings than Hillstream Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hillstream Biopharma	N/A	N/A	-$35.92M	-$0.50	N/A
Maase	$109.05M	2.46	-$27.36M	N/A	N/A

Hillstream Biopharma has a beta of 1.47, meaning that its stock price is 47% more volatile than the broader market. Comparatively, Maase has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market.

Summary

Maase beats Hillstream Biopharma on 7 of the 9 factors compared between the two stocks.

Get Hillstream Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNTN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNTN vs. The Competition

Export

Metric	Hillstream Biopharma	Financial Services Industry	Finance Sector	NASDAQ Exchange
Market Cap	$183.26M	$26.92B	$13.78B	$12.94B
Dividend Yield	N/A	6.31%	5.94%	12.80%
P/E Ratio	-4.60	19.28	25.32	25.40
Price / Sales	N/A	435.65	522.67	82.07
Price / Cash	N/A	49.60	30.07	34.74
Price / Book	0.21	3.20	2.73	6.32
Net Income	-$35.92M	$1.10B	$1.31B	$358.20M
7 Day Performance	9.52%	2.13%	-0.19%	0.42%
1 Month Performance	5.02%	10.25%	-0.25%	-3.30%
1 Year Performance	N/A	-2.06%	7.89%	5.33%

Hillstream Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNTN Hillstream Biopharma	0.0979 of 5 stars	$2.30 flat	N/A	N/A	$183.26M	N/A	N/A	12	High Trading Volume
FWDI Forward Industries	3.0856 of 5 stars	$6.08 -12.5%	$12.50 +105.6%	N/A	$513.24M	$18.19M	50.67	60	Gap Down
ACTG Acacia Research	1.6363 of 5 stars	$4.56 +1.8%	$6.00 +31.6%	+36.3%	$437.19M	$285.23M	N/A	986
TROO TROOPS	0.1471 of 5 stars	$2.30 +0.9%	N/A	+47.4%	$278.52M	$17.10M	N/A	47
CEPO Cantor Equity Partners	1.0345 of 5 stars	$10.76 +0.1%	N/A	+3.8%	$274.13M	N/A	N/A	2	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNTN) was last updated on 9/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hillstream Biopharma (CNTN) Competitors

CNTN vs. FWDI, ACTG, TROO, CEPO, and MAAS

How does Hillstream Biopharma compare to Forward Industries?

Summary

How does Hillstream Biopharma compare to Acacia Research?

Summary

How does Hillstream Biopharma compare to TROOPS?

Summary

How does Hillstream Biopharma compare to Cantor Equity Partners?

Summary

How does Hillstream Biopharma compare to Maase?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTN vs. The Competition

Hillstream Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hillstream Biopharma (CNTN) Competitors

CNTN vs. FWDI, ACTG, TROO, CEPO, and MAAS

How does Hillstream Biopharma compare to Forward Industries?

Does the media prefer CNTN or FWDI?

Which has more volatility and risk, CNTN or FWDI?

Which has preferable earnings and valuation, CNTN or FWDI?

Do analysts prefer CNTN or FWDI?

Is CNTN or FWDI more profitable?

Do insiders and institutionals hold more shares of CNTN or FWDI?

Summary

How does Hillstream Biopharma compare to Acacia Research?

Is CNTN or ACTG more profitable?

Does the media refer more to CNTN or ACTG?

Do analysts prefer CNTN or ACTG?

Do institutionals and insiders believe in CNTN or ACTG?

Which has preferable valuation & earnings, CNTN or ACTG?

Which has more volatility & risk, CNTN or ACTG?

Summary

How does Hillstream Biopharma compare to TROOPS?

Does the media favor TROO or CNTN?

Do institutionals & insiders have more ownership in TROO or CNTN?

Which has preferable earnings & valuation, TROO or CNTN?

Which has more risk & volatility, TROO or CNTN?

Do analysts prefer TROO or CNTN?

Is TROO or CNTN more profitable?

Summary

How does Hillstream Biopharma compare to Cantor Equity Partners?

Do analysts prefer CEPO or CNTN?

Do insiders and institutionals believe in CEPO or CNTN?

Which has more risk and volatility, CEPO or CNTN?

Is CEPO or CNTN more profitable?

Does the media favor CEPO or CNTN?

Which has stronger earnings & valuation, CEPO or CNTN?

Summary

How does Hillstream Biopharma compare to Maase?

Do analysts recommend CNTN or MAAS?

Do insiders & institutionals hold more shares of CNTN or MAAS?

Does the media refer more to CNTN or MAAS?

Is CNTN or MAAS more profitable?

Which has preferable earnings and valuation, CNTN or MAAS?

Which has more volatility & risk, CNTN or MAAS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTN vs. The Competition

Hillstream Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools